Heparin Belupo (Heparin Sodium)

Heparin Belupo is employed in clinical settings to manage and prevent clot‑related conditions. It is indicated for several therapeutic purposes:

• Prevention of venous thromboembolism in at‑risk patients.
• Treatment of acute coronary syndrome, including unstable angina and myocardial infarction.
• Prophylaxis of clot formation during surgical procedures.
• Management of thrombotic complications in patients undergoing cardiac catheterisation.
• Supportive anticoagulation during extracorporeal circulation such as dialysis.

Heparin Belupo may cause a range of adverse reactions, varying from mild to severe. Patients should be monitored for any signs of side effects.

Common

• Minor bleeding at the injection site or mucosal surfaces.
• Mild thrombocytopenia (reduced platelet count).
• Elevated liver enzymes indicating hepatic stress.
• Localised bruising or hematoma.
• Nausea or mild gastrointestinal discomfort.

Serious

• Heparin‑induced thrombocytopenia (HIT) with risk of new clot formation.
• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Spontaneous adrenal or retroperitoneal hemorrhage.
• Severe allergic reactions such as anaphylaxis.
• Disseminated intravascular coagulation (DIC).

Before initiating Heparin Belupo therapy, healthcare providers should consider several safety factors to minimise risk.

• Baseline and periodic monitoring of coagulation parameters (e.g., aPTT) and platelet counts.
• Caution in patients with a history of bleeding disorders or recent major surgery.
• Adjust dosing in individuals with renal or hepatic impairment.
• Evaluate pregnancy status; use only if the potential benefit outweighs risk.
• Elderly patients may require closer observation for bleeding.
• Ensure appropriate reversal agents are available in case of severe hemorrhage.

Heparin Belupo can interact with other medications, influencing its anticoagulant effect.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants).
• Antiplatelet agents such as aspirin, clopidogrel, or ticagrelor.
• Thrombolytic drugs (e.g., alteplase, streptokinase).
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• Certain antibiotics (e.g., vancomycin, quinolones) that may potentiate anticoagulation.
• ACE inhibitors and angiotensin receptor blockers, which can affect platelet function.
• Corticosteroids, due to potential additive effects on gastrointestinal bleeding.
• Herbal supplements like ginkgo biloba or garlic that have antiplatelet properties.